Tag: Padcev

Regulatory Approval News Oncology

PADCEV and Keytruda FDA Approval: Breakthrough Perioperative Treatment Cuts Bladder Cancer Death Risk by 50%

pfizer news

The FDA has approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as the first perioperative treatment regimen to significantly improve survival in cisplatin-ineligible patients with muscle-invasive bladder cancer. Based on pivotal Phase 3 EV-303 trial data, the combination demonstrated a 60% reduction in recurrence or death risk and a 50% reduction in mortality risk compared to surgery alone.

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

U.S. FDA Approves PADCEV® and KEYTRUDA® Combo for Patients with Bladder Cancer

pfizer news

The FDA has granted approval for PADCEV® plus KEYTRUDA® as a perioperative treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Clinical data reveals the combination reduces the risk of recurrence, progression, or death by 60% compared to surgery alone, marking a major shift in the standard of care.

Clinical Trials News Oncology

Breakthrough in Bladder Cancer Treatment: PADCEV and KEYTRUDA Combination Significantly Improves Survival

pfizer news

A landmark clinical trial reveals a powerful new weapon against aggressive bladder cancer. The combination of PADCEV™ and KEYTRUDA®, administered before and after surgery, has been shown to significantly improve survival rates for patients with muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy. These groundbreaking results could establish a new standard of care, offering profound hope for a patient population with previously limited options.